This article presents a patient who illustrates the current treatment techniques that optimize the efficacy and tolerability of poly-L-lactic acid.
The approach to soft tissue augmentation has evolved dramatically in recent years. With a greater appreciation for changes in facial soft tissue contours that occur with age has come an expansion of the role for fillers in rejuvenation of the midface. Ove
Poly-L-lactic acid (PLLA) was approved for use in Europe in 1999. In the United States, it was approved by the Food and Drug Administration in 2004 for the treatment of facial lipoatrophy associated with human immunodeficiency virus, and in 2009 for cosm
